Investment Rating - The report assigns a "Buy" rating to the company, with a current price of HKD 23.96 and a fair value of HKD 41.12 [8]. Core Insights - The company has formed a strategic partnership with Shiseido China to enhance its technology-driven skincare offerings, positioning itself as a leading platform for high-end skincare solutions tailored for Asian skin [8]. - The company aims to leverage its three major beauty brands (Meili Tianyuan, Nairui'er, and Siyuanli) to reshape the value landscape of the beauty industry, focusing on a dual beauty and health business model [8]. - The company is expected to maintain strong growth, with projected net profits of RMB 344 million, RMB 458 million, and RMB 600 million for the years 2025 to 2027, respectively [8]. Financial Summary - Revenue projections indicate a growth from RMB 2,145 million in 2023 to RMB 4,913 million in 2027, with growth rates of 31.2%, 19.9%, 16.9%, 33.7%, and 22.2% for the respective years [3][12]. - EBITDA is expected to increase from RMB 623 million in 2023 to RMB 1,170 million in 2027, reflecting a robust growth trajectory [3]. - The company's net profit margin is projected to improve from 10.7% in 2023 to 12.2% in 2027, indicating enhanced profitability [12]. - The report highlights a significant increase in return on equity (ROE), expected to rise from 26.9% in 2023 to 36.4% in 2027 [3][12].